title: Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression.
abstract: Inflammatory pathways play a crucial role in the pathomechanisms of antidepressant efficacy. The aim of this study was to investigate whether a set of single nucleotide polymorphisms (SNPs) within cyclooxygenase-2 (COX-2, rs5275 and rs20417) and oxytocin receptor (OXTR, rs53576 and rs2254298) genes was associated with antidepressant treatment resistance, response or remission. Three hundred seventy-two patients were recruited in the context of a multicenter resistant depression study. They were genotyped for COX-2 and OXTR SNPs. Treatment resistance (according to two different definitions), response and remission were recorded. We did not observe any association between the genotypes or alleles of the selected SNPs within COX-2 and OXTR genes and treatment resistance, response and remission in the whole sample. Our results are consistent with those of some studies but not with those of other ones. Indeed, several factors could be involved in the discrepancy observed across studies. They include sample size, environmental factors, differences in ethnicity, different study designs, and different definitions of treatment resistance.
authors.affiliation: Université Libre de Bruxelles, Belgium.
authors.forename: Julien
authors.initials: J
authors.lastname: Mendlewicz
authors.forename: Concetta
authors.initials: C
authors.lastname: Crisafulli
authors.forename: Raffaella
authors.initials: R
authors.lastname: Calati
authors.forename: Neslihan Aygun
authors.initials: NA
authors.lastname: Kocabas
authors.forename: Isabelle
authors.initials: I
authors.lastname: Massat
authors.forename: Sylvie
authors.initials: S
authors.lastname: Linotte
authors.forename: Siegfried
authors.initials: S
authors.lastname: Kasper
authors.forename: Martin
authors.initials: M
authors.lastname: Fink
authors.forename: Antonina
authors.initials: A
authors.lastname: Sidoti
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Scantamburlo
authors.forename: Marc
authors.initials: M
authors.lastname: Ansseau
authors.forename: Irina
authors.initials: I
authors.lastname: Antonijevic
authors.forename: Carlos
authors.initials: C
authors.lastname: Forray
authors.forename: Lenore
authors.initials: L
authors.lastname: Snyder
authors.forename: Joseph
authors.initials: J
authors.lastname: Bollen
authors.forename: Stuart
authors.initials: S
authors.lastname: Montgomery
authors.forename: Joseph
authors.initials: J
authors.lastname: Zohar
authors.forename: Daniel
authors.initials: D
authors.lastname: Souery
authors.forename: Alessandro
authors.initials: A
authors.lastname: Serretti
mesh_terms: D051546:Cyclooxygenase 2 / Q000235:genetics*; D003863:Depression / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy*; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology* / Q000235:genetics* / Q000517:prevention & control; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D015995:Prevalence; D018045:Receptors, Oxytocin / Q000235:genetics*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: C569600:OXTR protein, human; D018045:Receptors, Oxytocin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human